Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
GLP-1 (9-36) Amide: Research Guide
2026-09-16
GLP-1 (9-36) amide is a glucagon-like peptide-1 receptor antagonist used to interrogate GLP-1 receptor signaling in controlled research systems. Its product specifications, storage requirements, and interpretation limits should be separated from peer-reviewed evidence on related GLP-1 receptor ligands.
-
Rethinking GLP-1R Antagonism in Translational Research
2026-09-16
GLP-1 (9-36) amide can serve as a practical perturbation tool for resolving glucagon-like peptide-1 receptor signaling in complex metabolic systems. By integrating receptor-crosstalk controls, careful peptide handling, and translational assay logic, researchers can move beyond simple antagonist claims toward more reliable interpretation of GLP-1 receptor pathway data.
-
Indazole/Indole Glucagon Receptor Antagonists: SAR
2026-09-15
This 2015 Bioorganic & Medicinal Chemistry Letters study introduced indazole- and indole-based glucagon receptor antagonists derived from the pyrazole lead MK-0893. Systematic modification of the indazole C3, C6, and N1-benzylic positions produced compounds with strong in vitro activity, favorable rat pharmacokinetics, and acute glucose-lowering effects for GRA 16d in glucagon receptor humanized mouse models.
-
EZ Cap™ Cas9 mRNA for Neurodegeneration
2026-09-15
Use transient, chemically modified Cas9 expression to test gene function in sensitive neural and inflammatory models without committing to a DNA vector. This workflow connects Fyn–Stat3 zebrafish biology with practical CRISPR-Cas9 genome editing controls, delivery optimization, and phenotype-first validation.
-
PTH (1-34) Peptide: A CKD Assay Strategy
2026-09-14
Explore how the PTH (1-34) peptide fragment links receptor pharmacology with bone metabolism research and CKD-associated valvular calcification. This guide emphasizes endpoint-aware assay design, storage, controls, and interpretation beyond conventional osteoporosis models.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-09-14
The reference study identifies CD44 as a metabolic dependency in IDH-mutant leukemia, linking altered glucose flux to NADPH production and sustained R-2HG synthesis. Its isogenic CRISPR-based design supports combined metabolic and mutant-IDH targeting as a strategy for investigating resistance in AML.
-
Ibuprofen Toxicology and Biodegradation: Study Insights
2026-09-13
The 2023 Molecules review frames ibuprofen as an emerging contaminant by connecting widespread use with aquatic and soil exposure, toxicological effects, and difficult environmental removal. Its practical contribution is an integrated assessment of occurrence, oxidative and genotoxic stress, and bacteria-based biodegradation, while identifying major gaps in monitoring and treatment research.
-
H5N1 mRNA Vaccine Protects Lactating Dairy Cows
2026-09-12
A hemagglutinin-encoding mRNA–lipid nanoparticle vaccine protected lactating dairy cows from a high-dose H5N1 challenge while maintaining health and milk production. The study is notable for combining livestock safety data with evidence of durable protection that persisted even when serum antibody levels had declined substantially.
-
Ceftolozane Sulfate: Reliable Assay Workflows
2026-09-11
This scenario-based guide shows how Ceftolozane sulfate, SKU C8753, can support reproducible susceptibility, viability, and PK/PD workflows while preventing common interpretation errors. It connects assay design, resistance surveillance, storage, and product-selection decisions to the available product information and published comparative evidence.
-
Gefitinib (ZD1839) for EGFR Signaling Workflows
2026-09-11
Gefitinib (ZD1839) provides a practical way to test whether EGFR activity drives proliferation, stress responses, and pathway-dependent phenotypes. This guide connects established oncology assays with a carefully bounded skin-barrier application inspired by recent blue-light research, while emphasizing controls, dosing logic, and troubleshooting.
-
4-Hydroxytamoxifen: Protocol and QC Guide
2026-09-10
4-Hydroxytamoxifen (SKU B6167) provides a characterized, DMSO-compatible estrogen receptor modulator for controlled cell, cancer, apoptosis, and cardiac myocyte workflows. It should not be selected for protocols that require aqueous or ethanol dissolution, and long-term storage of prepared solutions should be avoided.
-
Imatinib hydrochloride: Research Workflow Guide
2026-09-10
Build reproducible kinase-inhibition assays with Imatinib hydrochloride for chronic myelogenous leukemia and gastrointestinal stromal tumor research. This guide combines target-proximal phosphorylation readouts with viability, timing, and conformation-aware controls while clearly separating established product data from exploratory assay recommendations.
-
Recombinant Mouse M-CSF in Fibrosis Assays
2026-09-09
Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) can standardize macrophage generation while preserving a clearer view of disease-specific signaling. This guide connects PM2021 with the IGF2BP1–THBS1–TLR4 pulmonary fibrosis axis and translates the evidence into better assay design.
-
hiPSC Intestinal Organoids for Pharmacokinetics
2026-09-09
Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be cryopreserved, differentiated into intestinal epithelial cells, and used to model transporter and CYP-mediated functions relevant to oral drug pharmacokinetics.
-
GLP-1 Receptor Crosstalk Revealed by FRET Assays
2026-09-08
Chepurny and colleagues used high-throughput cAMP FRET assays and molecular modeling to show that glucagon can activate the GLP-1 receptor, challenging the assumption that these related peptide receptors are pharmacologically isolated. The study also clarifies how orthosteric and allosteric antagonists can dissect receptor crosstalk and inform the design of dual- and triagonist strategies.